Company intelligence / Profile preview
NTC Pharma
Milano, Lombardia, Italyntcpharma.com ↗
- Ownership
- Private
- Employees
- ~249
- Development stage
- Commercial
01
Overview
NTC has conducted clinical trials involving thousands of patients, particularly in ophthalmology. Their study demonstrated the non-inferiority of NTC014 (antibiotic and NSAID combination) compared to an antibiotic alone for bacterial conjunctivitis, despite using a lower dose of antibiotic[1].
- Therapeutic areas
- GastroenterologyInfectious DiseasesOphthalmologyWomen's Health
- Modalities
- Drugsmedical devicesfood supplements
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
03
Partnerships
Distributors and partners in over 100 countries
Beyond the preview
Go deeper on NTC Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NTC Pharma.